NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Cerenome, Inc. (CNSY) Stock Analysis

Cerenome, Inc. (CNSY) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

CNSY

$1.73

+$0.05 (+2.98%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CNSY with… →

CNSY Key Statistics

As of Oct 21, 2026
Trading
Open
$1.68
Previous Close
$1.68
Day's Range
1.65–1.80
52-Week Range
1.49–19.00
Volume
53.82K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.47
Valuation
Market Cap
$12.75M
P/E Ratio
unprofitable
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
2.45
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
3.03
EPS (ttm)Profit attributable to each share over the last twelve months.
−3.36
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$22.39M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
7.59M
1-Year Return
−88.84%
Dividend and dates
Avg Volume
110.34K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, CNSY closed at $1.73, −88.84% over 1 year.

Cerenome, Inc. (CNSY) has a market capitalization of $12.75M.

In fiscal 2025, CNSY reported revenue of $0.00.

CNSY Stock Return by Calendar Year

Cerenome, Inc. (CNSY) 10-year return: what $10,000 became

1 year
$10,000 $1,116
−88.84%
5 years
$10,000 $27
−99.73%
10 years
$10,000 $0.05
−99.999%

If you had invested $10,000 in Cerenome, Inc. (CNSY) 10 years ago, at the close on October 21, 2016, it would have been worth $0.05 at the close on October 21, 2026: −99.999% in total, −70.49% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−86.43%
2025−55.65%
2024−34.29%
2023−63.54%
2022−69.52%
2021−48.02%
2020−15.83%
2019−83.45%
2018−90.33%
2017−80.13%
2016 (partial year)−26.70%

As of October 21, 2026.

CNSY Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$22.39M—
2024$0.00−$12.98M—
2023$0.00−$13.32M—
2022$0.00−$20.28M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$15.30M−$22.39M—
2024$0.00—−$14.70M−$12.98M—
2023$0.00—−$13.32M−$13.32M—
2022$0.00—−$19.71M−$20.28M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

CNSY Valuation vs Biotechnology Median

Median of 608 stocks
MetricCNSYBiotechnology medianvs median
P/S ratio3.0313.300.2x the median

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 16 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Cerenome, Inc. (CNSY) is capitalised at $12.75M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 28 employees.

Over the past 52 weeks the price has ranged from $1.49 to $19.00. CNSY last closed at $1.73 on October 21, 2026. That is +$0.05 (+2.98%) against the previous close. The latest close sits 16.11% above that 52-week low.

Financial Health

In fiscal 2025, Cerenome, Inc. reported revenue of $0.00. The same year closed with a net loss of $22.39M. Earnings per share on a trailing basis come to −3.36.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The PEG ratio, which sets the P/E against expected earnings growth, reads 2.45. Measured against sales, the shares trade at 3.03 times revenue. On price-to-sales that is 0.2 times the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

The trailing one-year total return is −88.84%. Measured over 10 years, that is −70.49% a year compounded. Beta against the wider market is reported at 1.47. Annualized volatility over the trailing 10 years is 184.88%.

Growth & Income

No dividend is on file for CNSY.

Across the complete calendar years on file, 2020 returned −15.83% and 2018 returned −90.33%. Of the 9 complete calendar years on file, 0 finished higher. 2026 is still running; the total return is −86.43% year to date.

Peer Comparison

Cerenome, Inc. (CNSY) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Cerenome, Inc. CNSY $12.75M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Cerenome, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Cerenome, Inc.

Cerenome, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid organ cancers, such as primary and secondary liver cancers, by intra-arterial injection. In addition, it develops and commercializes laboratory-developed tests comprising the CNSide Test to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas, as well as develops a data analytics and artificial intelligence platform to integrate diverse data sets into actionable insights that support precision oncology, therapeutic development, and clinical decision-making. The company was formerly known as Plus Therapeutics, Inc. and changed its name to Cerenome, Inc. in August 2026. Cerenome, Inc. was founded in 1996 and is headquartered in Houston, Texas.

Visit website →